Core Insights - BioHarvest Sciences reported a 47% increase in first-quarter revenues, reaching $7.9 million, surpassing management's guidance [3][8][11] - The growth was primarily driven by the VINIA® business, which achieved over 50,000 active subscribers by February 2025 [3][5] - The company is expanding its product offerings and marketing strategies to target younger consumer segments [4][7] Financial Performance - Total revenues for Q1 2025 increased to $7.9 million from $5.3 million in Q1 2024, marking a 47% year-over-year growth [8] - Gross profit rose by 53% to $4.6 million, with gross margins improving to 58.5% from 56.2% [9][22] - Operating expenses increased to $6.3 million, primarily due to higher marketing expenditures, but as a percentage of revenue, it decreased to 46.8% from 48.0% [10][22] Loss and Financing - The net loss for Q1 2025 was $2.3 million, a significant reduction from a net loss of $6.6 million in the same quarter of the previous year [11][22] - The company raised $3.9 million in debt financing during the quarter, increasing cash and cash equivalents to $3.4 million [12][24] Operational Highlights - The company is advancing its CDMO division, with successful validation of its botanical synthesis platform for various molecule types [5][6] - New product lines under the VINIA® brand are being introduced, including VINIA® SuperFood Tea and VINIA® Espresso, aimed at capturing a younger demographic [4][7] - The company anticipates continued growth in both its product and service units, with expectations of reaching adjusted EBITDA breakeven in the second half of 2025 [5][7]

Core Insights - BioHarvest Sciences Inc. has successfully progressed its CDMO contract with a Nasdaq-listed pharmaceutical company from Stage 1 to Stage 2, validating its Botanical Synthesis platform for developing active pharmaceutical compounds [1][4] Group 1: Contract Development and Manufacturing Organization (CDMO) Progress - Stage 1 of the contract, initiated in early 2024, involved sourcing plants to develop a compound for an approved drug product, which has now been completed successfully [2] - The successful completion of Stage 1 indicates that the research team isolated and multiplied the target plant cells using the proprietary Botanical Synthesis platform [2] - Stage 2 will focus on delivering sufficient biomass for testing and developing optimal growing conditions, leading to small and medium-scale production and eventually commercial volume production [3] Group 2: Company Statements and Future Outlook - The CEO of BioHarvest expressed excitement about advancing to Stage 2, highlighting the milestone as a validation of the platform's versatility and its potential to provide cost-effective alternatives to traditional sourcing methods [4] - The Chairman of the CDMO Division noted that Stage 1 carried the highest technical risk, and its successful completion demonstrates the platform's capability to address a wide range of molecule families, with Stage 2 expected to have a higher probability of success [4]

The market expects BioHarvest Sciences Inc. (BHST) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to ...

Unaudited Interim Condensed Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2024 Expressed in U.S. dollars in thousands BioHarvest Sciences Inc. BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2024 Expressed in U.S. dollars in thousands TABLE OF CONTENTS | | Page | | --- | --- | | FINANCIAL STATEMENTS: | | | Unaudited Interim Condensed Consolidated Statements of Financial Position | 3 ...

BioHarvest Sciences Inc. 2 BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Financial Statements For the Three and Six Months Ended June 30, 2024 Expressed in U.S. dollars in thousands BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Financial Statements For the Three and Six Months Ended June 30, 2024 Expressed in U.S. dollars in thousands TABLE OF CONTENTS | | Page | | --- | --- | | FINANCIAL STATEMENTS: | | | Unaudited Interim Condensed Consolidated Statements of Financi ...